Sandra Calvin, SVP, Chief Accounting Officer: Travere Therapeutics TVTX Sell · Filed 24/01/25

Trade details

Type: Insider sale
Amount: $8,253.7
Shares · price: 910 sh · $9.07 a share
Held after: 41,337 sh
Stock: Travere Therapeutics TVTX
Person: Sandra CalvinSVP, Chief Accounting Officer
Trade date: 24/01/23
Filed: 24/01/25
Days to filing: 2 days

Sold 2.2% of holdings

Share of holding sold: 2.2%

Travere Therapeutics trades, last 26 weeks

What else happened in Travere Therapeutics around then

Filed or reported within 30 days of the trade day · 23/12/24~24/02/22

Sandra Calvin's recent trades

Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$353.6K
5,375 sh
$353.6K
Filed 09/15
Traded 09/15
Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/16
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/14
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned saleTravere Therapeutics
Planned sale
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
SellTravere Therapeutics
Sell
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03